title: The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome.
abstract: OBJECTIVE
  Women with polycystic ovary syndrome (PCOS) have multiple risk factors for cardiovascular disease. The cardiovascular risk marker homocysteine (Hcy) is elevated in women with PCOS. This prospective study investigated the effect of oral contraceptives containing ethinyl estradiol-cyproterone acetate (EE-CA) on serum Hcy levels in women with PCOS.
  
  
  METHODS
  A total of 30 women with PCOS were enrolled in this prospective study. The diagnosis of PCOS was made according to the criteria of the Rotterdam PCOS consensus workshop group. All women took oral contraceptives containing EE/CA (35 microg/2 mg) for 3 months. Serum samples for Hcy, lipid profile and hormones were obtained during the early follicular phase (days 3-5) of the spontaneous or progestin-induced bleeding at baseline, and after the third treatment cycle.
  
  
  RESULTS
  Three months of EE-CA therapy significantly decreased the Hcy levels from 55.97 +/- 16.04 to 54.03 +/- 16.15 (P = 0.01). A significant correlation was observed between the Hcy and total and free testosterone levels (r = 0.44, P = 0.015 and r = 0.46, P = 0.001 respectively).
  
  
  CONCLUSIONS
  Although the decrease in Hcy levels with EE-CA therapy was statistically significant, further studies are necessary to determine the clinical benefit of this treatment.
authors.affiliation: School of Medicine, Department of Obstetrics and Gynecology, Duzce University, Konuralp, Duzce, Turkey.
authors.forename: Ozgur Baris
authors.initials: OB
authors.lastname: Gul
authors.forename: Asli
authors.initials: A
authors.lastname: Somunkiran
authors.forename: Oguz
authors.initials: O
authors.lastname: Yucel
authors.forename: Fuat
authors.initials: F
authors.lastname: Demirci
authors.forename: Ismail
authors.initials: I
authors.lastname: Ozdemir
mesh_terms: D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use*; D003278:Contraceptives, Oral, Hormonal / Q000627:therapeutic use; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D004338:Drug Combinations; D004967:Estrogens / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D005498:Follicular Phase; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D008055:Lipids / Q000097:blood; D009765:Obesity / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D011446:Prospective Studies; D013739:Testosterone / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D003278:Contraceptives, Oral, Hormonal; D004338:Drug Combinations; D004967:Estrogens; D008055:Lipids; D006710:Homocysteine; D013739:Testosterone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate